openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS To avoid potassium intoxication, infuse potassium containing solutions slowly. In patients with severe renal insufficiency or adrenal insufficiency, administration of Potassium Acetate for Injection, USP CONCENTRATE may cause potassium intoxication. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
ADVERSE REACTIONS Nausea, vomiting, abdominal pain and diarrhea have been reported. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of p waves, spreading and slurring of the QRS complex with development of a biphasic curve, and cardiac arrest. See WARNINGS . USE IN PREGNANCY Safety for use in pregnancy has not been established. Use of potassium acetate in women of childbearing potential requires that anticipated benefits be weighed against possible hazards.